... Jul 17
Recommendation based on positive results from the Phase 3 CheckMate -577 trial in which Opdivo doubled disease-free survival compared to placebo in the all-... Jun 25
... Jan 05
If approved, Zeposia would be the first oral sphingosine-1-phosphate (S1P) receptor modulator for the treatment of ulcerative colitis.... Dec 28
... Dec 23
If approved, Inrebic will become the first new therapy for myelofibrosis in Europe in nearly a decade.... Dec 11
Results demonstrated treatment with Onureg improved overall survival, compared to placebo, in patients with AML in first remission.... Dec 08
Bristol Myers Squibb announced the approval of Opdivo for the treatment of adults with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma ... Nov 25
The Bristol Myers Squibb–Pfizer Alliance, with the support of leading advocacy organizations and medical societies, announces the launch of the No Time to Wait ... Oct 26
Results from CheckMate -9ER recently presented during a Presidential Symposium at the European Society for Medical Oncology Virtual Congress... Oct 19
-Advertisements-
.jpeg)
Tuesday, April 29, 2025
.jpg)
.jpeg)
.jpeg)
.jpeg)
.jpeg)
.jpeg)
.jpeg)
.jpeg)
.jpeg)
.jpeg)
.jpeg)
.jpeg)
